Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry

Citations Over TimeTop 10% of 2023 papers

Abstract

Drug-drug interactions (DDIs) involving hepatic organic anion transporting polypeptides 1B1/1B3 (OATP1B) can be substantial, however, challenges remain for predicting interaction risk. Emerging evidence suggests that endogenous biomarkers, particularly coproporphyrin-I (CP-I), can be used to assess in vivo OATP1B activity. The present work under the International Consortium for Innovation and Quality in Pharmaceutical Development was aimed primarily at assessing CP-I as a biomarker for informing OATP1B DDI risk. Literature and unpublished CP-I data along with pertinent in vitro and clinical DDI information were collected to identify DDIs primarily involving OATP1B inhibition and assess the relationship between OATP1B substrate drug and CP-I exposure changes. Static models to predict changes in exposure of CP-I, as a selective OATP1B substrate, were also evaluated. Significant correlations were observed between CP-I area under the curve ratio (AUCR) or maximum concentration ratio (C_max R) and AUCR of substrate drugs. In general, the CP-I C_max R was equal to or greater than the CP-I AUCR. CP-I C_max R max R < 2 was associated with weak OATP1B-mediated DDIs (AUCR < 2). A correlation was identified between CP-I exposure changes and OATP1B1 static DDI predictions. Recommendations for collecting and interpreting CP-I data are discussed, including a decision tree for guiding DDI risk assessment. In conclusion, measurement of CP-I is recommended to inform OATP1B inhibition potential. The current analysis identified changes in CP-I exposure that may be used to prioritize, delay, or replace clinical DDI studies.

Related Papers

• INVESTIGATING THE FACTORS AFFECTING DRUG-DRUG INTERACTIONS(2013)
• [Drug-drug interaction and drug-induced interference with clinical laboratory test procedures--drug interaction in biopharmaceutics (author's transl)].(1975)
• [Drug-drug interaction and drug-induced interference with clinical laboratory test procedures--endocrine function tests and drug interferences (author's transl)].(1975)
• [Drug-drug interaction and drug-induced interference with clinical laboratory test procedures--clinical pharmacological approaches to drug-interactions (author's transl)].(1975)
• → Pilot Study: Assessment of Drug-Food and Drug-Drug Interactions in the Outpatient Settings(2020)